Chinese hamster ovary (CHO) cells play a vital role in the production of recombinant therapeutic proteins (RTPs), particularly therapeutic antibodies, which are booming in the pharmaceutical market. The global biopharmaceutical market size reached 336.6 billion USD in 2021, with monoclonal antibodies accounting for a significant portion and expected growth in the coming years. Mammalian cells, especially CHO cells, are favored for their similarity to human post-translational modifications, making them a prominent platform for RTP production. CHO cells offer advantages such as scalability, ease of integration, and production of proteins with human-like PTMs. Despite advancements in culture media optimization and expression vectors, issues like cell clone heterogeneity and product aggregation persist, impacting RTP yield and quality.
Strategies to Address Cell Clone Heterogeneity
The development of recombinant CHO cell lines involves various stages from transgene cloning to culture process optimization. Current cell clone screening methods, predominantly relying on random transgene integration (RTI), result in high cell clone heterogeneity due to varied gene expression levels and stability among clones. Transposase-mediated semi-targeted integration (STI) systems have shown promise in addressing clonal heterogeneity by enabling precise integration at specific genomic sites. Site-specific integration (SSI) methods, such as CRISPR/Cas9, aim to reduce heterogeneity by integrating transgenes at predefined loci, shortening screening times, and enhancing clone stability. However, challenges like low copy numbers and off-target effects limit the widespread application of SSI in industrial settings.
Cell Line Characteristics and Heterogeneity
CHO cell lines exhibit chromosomal variations and genomic instability, leading to genotype and phenotype drift over extended culture periods. Genomic analyses have identified stable CHO-K1 cells and gene-edited CHO-GS lines as promising options for industrial production. Strategies to enhance cell anti-apoptotic abilities and increase growth rates have been explored to maintain clone stability and improve productivity. Transcriptional silencing, influenced by factors like DNA methylation and histone modifications, plays a role in transgene expression instability, impacting RTP yields.
Mechanisms of Recombinant Protein Aggregation
Protein aggregation, a common challenge in RTP production, can significantly impact product safety and efficacy. Inefficient processing in the endoplasmic reticulum (ER) and Golgi apparatus, caused by high protein loads, contributes to aggregation. Factors like protein structure, glycosylation patterns, and environmental conditions influence protein folding and aggregation. Strategies to prevent aggregation include upregulating ER-resident chaperones, optimizing culture conditions, and using specific promoters to enhance protein stability and secretion.
Strategies to Mitigate Protein Aggregation
Molecular structures, cell culture conditions, and protein secretion efficiency are critical factors affecting protein aggregation. Optimizing culture media compositions, adjusting culture parameters like temperature and pH, and enhancing ER-related mechanisms can reduce aggregation levels. Technologies such as CrossMab and tcBsIgG have been developed to prevent antibody aggregation, ensuring correct folding and improving product quality. Multi-omics data and AI technologies offer promising avenues for reducing heterogeneity in CHO cell expression systems and enhancing RTP production.
In conclusion, understanding the complexities of cell clones and protein heterogeneity in CHO cell systems is crucial for ensuring consistent RTP quality. By addressing challenges related to cell clone heterogeneity, protein aggregation, and cell line characteristics, the biopharmaceutical industry can advance towards more efficient and reliable production of therapeutic proteins.
Key Takeaways:
- Cell clone heterogeneity in CHO cell systems impacts RTP yield and quality.
- Strategies like STI and SSI aim to reduce clonal heterogeneity and enhance clone stability.
- Protein aggregation poses challenges to RTP production, affecting safety and efficacy.
- Optimization of culture conditions and molecular structures can mitigate protein aggregation.
- Advancements in multi-omics data and AI technologies offer opportunities to enhance RTP production.
Tags: secretion, yeast, regulatory, chaperones, scale up, cell culture, monoclonal antibodies, protein folding, downstream
Read more on pmc.ncbi.nlm.nih.gov